- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Key Considerations for Treating Patients Diagnosed With CLL and SLL
Medical experts provide their final thoughts regarding key treatment considerations for CLL and SLL.
EP: 1.Clinical Characteristics Distinguishing CLL and SLL
EP: 2.Quality of Life Impacted By CLL and SLL Diagnosis and Management
EP: 3.Evaluating Current Treatment Landscape of CLL and SLL
EP: 4.Unmet Needs In CLL and SLL Treatment Management
EP: 5.Indications and Considerations For BTK Inhibitor Use In CLL and SLL Management
EP: 6.Examining Safety and Efficacy of BTK Inhibitors In CLL and SLL Treatment
EP: 7.Determining Optimal CLL / SLL Therapy: Ibrutinib, Acalabrutinib and Zanubrutinib
EP: 8.Key Highlights From ASH 2023
EP: 9.Economic Burden Associated With BTK Inhibitor Use
EP: 10.Patient Education Driving BTK Inhibitor Treatment Adherence
EP: 11.Optimizing BTKi Treatment Strategies
EP: 12.Key Considerations for Treating Patients Diagnosed With CLL and SLL
This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA, CPEL; Tara Graff, DO, MS; Ryan Jacobs, MD; Deborah Stephens, DO; Jennifer Woyach, MD.
In their concluding remarks, the group emphasizes that although there are exciting new treatment options for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), a one-size-fits-all approach does not apply. Therapies need to be selected on an individual basis considering factors like safety profiles, cost-effectiveness, and optimal sequencing.
Dr Stephens notes that those patients in the “watch and wait” category also need support managing anxiety around when to start treatment. As options rapidly evolve, early intervention may someday be warranted for high-risk patients to access the latest therapies at disease progression. But ensuring access to appropriate supportive care like vaccines and cancer screenings remains crucial regardless of treatment status.
With drastically improved survival rates, patients are now expected to live normal life spans. So developing additional tolerable treatment options and optimal combination strategies and ensuring vigilant, supportive care are pivotal to enable patients to live decades in quality remission. Overall this is an encouraging era, but personalization based on a patient’s unique medical profile remains key to maximize outcomes.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
